A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
AVZO-023 follows AVZO-021 into clinical trials.
A phase 2/3 study might show whether teliso-A can do better than teliso-V.
The move follows promising but early data presented at ASCO.
The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.
First-in-human trial starts include 3SBio's SSGJ-708 and in vivo Car-Ts from Legend and Starna.
PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.
